SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on March 6, 2003; DOI 10.1182/blood-2002-12-3802. This Article Full Text (PDF) All Versions of this Article: 2002-12-3802v1 101/12/4850    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gris, J.-C. Articles by Mares, P. Search for Related Content PubMed PubMed Citation Articles by Gris, J.-C. Articles by Mares, P. Social Bookmarking                   What's this? Submitted December 17, 2002 Accepted February 12, 2003 Anti-protein Z antibodies in women with pathological pregnancies Jean-Christophe Gris*, Cecile Amadio, Eric Mercier, Geraldine Lavigne-Lissalde, Herve Dechaud, Mederic Hoffet, Isabelle Quere, Jean Amiral, Michel Dauzat, and Pierre Mares Laboratoire d'Hematologie, UFR des Sciences Pharmaceutiques et Biologiques, Universite Montpellier I, Montpellier, France Laboratoire d'Hematologie, Centre Hospitalier Universitaire, Nimes, France EA 2992, Nimes, France Departement de Gynecologie et Obstetrique, Centre Hospitalier Universitaire, Nimes, France Hyphen BioMed, Andresy, France * Corresponding author; email: jcgris{at}chu-nimes.fr. Protein Z deficiencies have recently been described in women with unexplained early fetal loss. Using a new, specifically elaborated, commercially-available E.L.I.S.A., we performed a case-control study on anti-protein Z IgG and IgM antibodies in 191 non-thrombotic, non-thrombophilic consecutive women with pathological pregnancies. Levels of anti-protein Z antibodies were categorized in three strata (percentiles 1-74, 75-97, 98-100 among controls). The two upper levels of IgG and IgM anti-protein Z antibodies were associated with the risk of unexplained recurrent embryo loss or fetal death independently from habitual antiphospholipid/anticofactor antibodies and a dose-effect relationship between antibody levels and the clinical risks was evidenced. In women, enhanced immune complexes formation with protein Z may play a role in unexplained embryo losses and, from the 10th week of gestation, may favor hypercoagulability in the maternal placenta side. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. M. Abo and V. A. DeBari Laboratory Evaluation of the Antiphospholipid Syndrome Ann. Clin. Lab. Sci., January 1, 2007; 37(1): 3 - 14. [Abstract] [Full Text] [PDF] M. Bern Observations on Possible Effects of Daily Vitamin K Replacement, Especially Upon Warfarin Therapy JPEN J Parenter Enteral Nutr, November 1, 2004; 28(6): 388 - 398. [Abstract] [Full Text] [PDF] V. Hurtado, R. Montes, J.-C. Gris, M. L. Bertolaccini, A. Alonso, M. A. Martinez-Gonzalez, M. A. Khamashta, K. Fukudome, D. A. Lane, and J. Hermida Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death Blood, September 1, 2004; 104(5): 1369 - 1374. [Abstract] [Full Text] [PDF] J.-C. Gris, E. Mercier, I. Quere, G. Lavigne-Lissalde, E. Cochery-Nouvellon, M. Hoffet, S. Ripart-Neveu, M.-L. Tailland, M. Dauzat, and P. Mares Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder Blood, May 15, 2004; 103(10): 3695 - 3699. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020